Myovant Sciences

Operator of a drug discovery and therapeutics company intended to treat and prevent the formation of metastatic disease. The company combines artificial intelligence, bioinformatics, and proprietary imaging techniques to identify which cancers are more likely to spread, enabling healthcare professionals to identify targets quicker, select the appropriate patients for therapy effectively, and improve patient outcomes.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Developer of polymeric therapeutics and vaccines designed to meet medical needs. The company focuses on amplifying the impact of vaccines and therapeutics by using its self-amplifying ribonucleic acid platform to provide enhanced protein expression, combining tolerability with slow release and thermostability, enabling patients to get treatment for rare diseases.